Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors
This is an open label, dose escalation study to determine the maximum tolerated dose (MTD)
of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid
tumors. There will be a dose expansion cohort of thirty patients to assess detailed
pharmacokinetics and to assess any signal of activity in patients with solid tumors and in a
portion who have breast cancer that is triplenegative (ER-negative, PR-negative, and
HER2-negative).
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Establish the maximum tolerated dose (MTD) of pazopanib with weekly paclitaxel and carboplatin on a 28- day cycle
Toxicity will be assessed every 28 days up to 30 days after the last dose of treatment. Dose limiting toxicity is defined as Non-hematological toxicity ≥ grade 3 (excluding alopecia, nausea, vomiting, or diarrhea for which adequate supportive therapy has not been instituted). Hematologic toxicity: Grade 4 neutropenia lasting ≥ 7 days Grade 4 neutropenia and fever of ≥ 38.5°C ≥ Grade 3 neutropenia with ≥ Grade 3 infection Grade 4 thrombocytopenia Inability to start next cycle of treatment by more than 4 weeks due to unresolved toxicity
Up to 30 days after last dose of treatment
Yes
Antoinette Tan, MD
Principal Investigator
University of Medicine and Dentisty of New Jersey - Cancer Institute of New Jersey
United States: Food and Drug Administration
051101
NCT01407562
August 2011
December 2013
Name | Location |
---|---|
Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |